What Is Huperzine A?

Huperzine A is used for benign memory impairment and all types of dementia, memory cognitive function and emotional behavior disorder in middle and old age. Can still be used to treat myasthenia gravis.

Huperzine A is used for benign memory impairment and all types of dementia, memory cognitive function and emotional behavior disorder in middle and old age. Can still be used to treat myasthenia gravis.

Drug type

Essential medicines

Drug name

Huperzine A

English name

Huperzine-A

Chinese alias

Fordine; Haberin; Bamboo Forest

English alias

Haboyin; Selagine

(5R, 9R, 11E) -5-amino-11-ethylene-5,8,9,1o-tetrahydro-7-methyl-5,9-methylenecyclooctatetraene [b] pyridine -2- (1H) -one

C15H18N20

242

It is a slightly yellow crystalline powder and is almost insoluble in water.

This product is a reversible cholinesterase inhibitor, which has a selective inhibitory effect on true cholinesterase. High biological activity, high fat solubility, small molecules, easy to pass through the blood-brain barrier, and more distributed in the brain's frontal, temporal, hippocampus and other areas of the brain that are closely related to learning and memory after entering the center, At low doses, it has a strong inhibitory effect on acetylcholinesterase (AChE), which significantly increases the content of acetylcholine (ACh) in the synaptic space in the distribution area, thereby enhancing neuronal excitability transmission and strengthening learning and memory brain area excitement. The role is to improve cognitive function, enhance memory retention and promote memory reproduction. Animal experiments have shown that this product is rapidly and completely absorbed orally, with a bioavailability of 96%, which can reach peak blood drug concentrations in 10-30 minutes, has a fast distribution, and easily crosses the blood-brain barrier. The elimination half-life is 4 hours. It is excreted mainly in the form of urine and metabolites, and 73.6% of the dose is excreted in 24 hours.

It is used for benign memory disorders and dementias, memory cognitive function and emotional behavior disorders in middle and old age. Can still be used to treat myasthenia gravis.

Due to different dosage forms and specifications, please read the drug instructions carefully or follow the doctor's advice.

See donepezil. Occasionally nausea, dizziness, sweating, abdominal pain, blurred vision, etc. Individual patients have dilated pupils, vomiting, heart rate changes, drooling, and drowsiness.

Those who are allergic to this medicine, severe bradycardia, hypotension, angina pectoris, epilepsy, asthma, intestinal obstruction, renal insufficiency, and urinary tract obstruction are contraindicated.

There are individual differences in the dosage of the drug, and generally the drug should be started from a small dose. If an adverse reaction occurs, the symptoms can be alleviated or disappeared after reducing the dose; in severe cases, the drug should be stopped before using atropine to counteract the symptoms.

See donepezil. This product is cautiously compatible with alkaline drugs.

Tablets and capsules: 50g

[Identification] (1) Take about 0.2mg of this product, add 5 drops of ethanol to dissolve it, and add 2 drops of bismuth potassium iodide test solution to form an orange-yellow precipitate. (2) In the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution is consistent with the retention time of the main peak of the reference solution. (3) The infrared light absorption spectrum of this product should be consistent with the control spectrum (spectrum set 936). [Check] Clarity of acid solution: Take 5mg of this product, add 5ml of 0.1mol / L hydrochloric acid solution to dissolve, the solution should be clear. Relevant substances: take this product, dissolve it with 0.01mol / L hydrochloric acid solution and make a solution containing 0.1mg per 1ml, as the test solution; take a precise amount, and use 0.01mol / L hydrochloric acid solution to make every 1ml A 2.5 g solution was used as a control solution. According to the chromatographic conditions under the content determination item, take 20 l of the reference solution and inject it into the liquid chromatograph, adjust the detection sensitivity so that the peak height of the main component chromatographic peak is about 10% of the full range, and then accurately measure the test solution and the reference solution. Each 20 l was injected into a liquid chromatograph, and the chromatogram was recorded to twice the retention time of the main component chromatographic peak. If there is an impurity peak in the chromatogram of the test solution, the sum of the area of each impurity peak must not be greater than the area of the main peak of the control solution (2.5%). Loss on drying: Take about 0.3g of this product and dry it at 80 under reduced pressure to constant weight. The weight loss should not exceed 4.0% (Appendix L). [Content determination] Determination according to high performance liquid chromatography (Appendix V D). Chromatographic conditions and system suitability test using octadecylsilane bonded silica gel as filler; acetonitrile-phosphate buffer solution (take 2.72 g of potassium dihydrogen phosphate, add 1000 ml of water to dissolve, adjust the pH value to 2.5 with phosphoric acid) (14 : 86) is the mobile phase; the detection wavelength is 310 nm. The theoretical number of plates calculated from Huperzine A peak is not less than 2000. Take the appropriate amount of this product by measurement, accurately weigh it, dissolve it with 0.01mol / L hydrochloric acid solution and quantitatively dilute it to make a solution containing about 40g per 1ml. Precisely measure 20l into the liquid chromatograph and record the chromatogram. The appropriate amount of base A reference substance was determined by the same method. Calculate the peak area according to the external standard method. [Category] Cholinesterase inhibitor. [Storage] shading and sealed.

^{[1] [2] [3] [4]}